{"id":"https://openalex.org/W4281691007","doi":"https://doi.org/10.1200/jco.2022.40.16_suppl.103","title":"Circulating tumor DNA (ctDNA) and late recurrence in high-risk, hormone receptor\u2013positive, HER2-negative breast cancer (CHiRP).","display_name":"Circulating tumor DNA (ctDNA) and late recurrence in high-risk, hormone receptor\u2013positive, HER2-negative breast cancer (CHiRP).","publication_year":2022,"publication_date":"2022-06-01","ids":{"openalex":"https://openalex.org/W4281691007","doi":"https://doi.org/10.1200/jco.2022.40.16_suppl.103"},"language":"en","primary_location":{"id":"doi:10.1200/jco.2022.40.16_suppl.103","doi":"https://doi.org/10.1200/jco.2022.40.16_suppl.103","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2022.40.16_suppl.103","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5022530360","display_name":"Marla D. Lipsyc-Sharf","orcid":"https://orcid.org/0000-0002-4071-6383","observed_orcids":["https://orcid.org/0000-0002-4071-6383"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Marla Lipsyc-Sharf","raw_affiliation_strings":["Dana-Farber Cancer Institute, Boston, MA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dana-Farber Cancer Institute, Boston, MA;","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5059721552","display_name":"Elza C. de Bruin","orcid":"https://orcid.org/0000-0002-8996-8354","observed_orcids":["https://orcid.org/0000-0002-8996-8354"]},"institutions":[{"id":"https://openalex.org/I105036370","display_name":"AstraZeneca (United Kingdom)","ror":"https://ror.org/04r9x1a08","country_code":"GB","type":"company","lineage":["https://openalex.org/I105036370"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Elza De Bruin","raw_affiliation_strings":["AstraZeneca, Cambridge, United Kingdom;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"AstraZeneca, Cambridge, United Kingdom;","institution_ids":["https://openalex.org/I105036370"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5102799583","display_name":"Katheryn Santos","orcid":"https://orcid.org/0000-0002-3945-7644","observed_orcids":["https://orcid.org/0000-0002-3945-7644"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Katheryn Santos","raw_affiliation_strings":["Dana-Farber Cancer Institute, Boston, MA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dana-Farber Cancer Institute, Boston, MA;","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5009167161","display_name":"Robert K. McEwen","orcid":"https://orcid.org/0009-0000-7155-5714","observed_orcids":["https://orcid.org/0009-0000-7155-5714"]},"institutions":[{"id":"https://openalex.org/I105036370","display_name":"AstraZeneca (United Kingdom)","ror":"https://ror.org/04r9x1a08","country_code":"GB","type":"company","lineage":["https://openalex.org/I105036370"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Robert McEwen","raw_affiliation_strings":["AstraZeneca Pharmaceuticals LP, Cambridge, United Kingdom;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"AstraZeneca Pharmaceuticals LP, Cambridge, United Kingdom;","institution_ids":["https://openalex.org/I105036370"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5037122637","display_name":"Daniel Stetson","orcid":"https://orcid.org/0000-0002-3961-2739","observed_orcids":["https://orcid.org/0000-0002-3961-2739"]},"institutions":[{"id":"https://openalex.org/I4210150756","display_name":"AstraZeneca (United States)","ror":"https://ror.org/043cec594","country_code":"US","type":"company","lineage":["https://openalex.org/I105036370","https://openalex.org/I4210150756"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Daniel Stetson","raw_affiliation_strings":["AstraZeneca, Waltham, MA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"AstraZeneca, Waltham, MA;","institution_ids":["https://openalex.org/I4210150756"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5064407331","display_name":"Ashka Patel","orcid":"https://orcid.org/0009-0004-6128-5510","observed_orcids":["https://orcid.org/0009-0004-6128-5510"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ashka Patel","raw_affiliation_strings":["Dana-Farber Cancer Institute, Boston, MA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dana-Farber Cancer Institute, Boston, MA;","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5011491566","display_name":"Gregory John Kirkner","orcid":"https://orcid.org/0009-0005-0386-5223","observed_orcids":["https://orcid.org/0009-0005-0386-5223"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Gregory J. Kirkner","raw_affiliation_strings":["Dana Farber Cancer Institute, Boston, MA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dana Farber Cancer Institute, Boston, MA;","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5015055171","display_name":"Melissa E. Hughes","orcid":"https://orcid.org/0000-0001-6190-9101","observed_orcids":["https://orcid.org/0000-0001-6190-9101"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Melissa E. Hughes","raw_affiliation_strings":["Dana-Farber Cancer Institute, Boston, MA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dana-Farber Cancer Institute, Boston, MA;","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5069056507","display_name":"Sara M. Tolaney","orcid":"https://orcid.org/0000-0002-5940-8671","observed_orcids":["https://orcid.org/0000-0002-5940-8671"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Sara M. Tolaney","raw_affiliation_strings":["Dana-Farber Cancer Institute, Boston, MA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dana-Farber Cancer Institute, Boston, MA;","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5032785430","display_name":"Ian E. Krop","orcid":"https://orcid.org/0000-0002-6380-5944","observed_orcids":["https://orcid.org/0000-0002-6380-5944"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ian E. Krop","raw_affiliation_strings":["Dana-Farber Cancer Institute, Boston, MA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dana-Farber Cancer Institute, Boston, MA;","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5068512346","display_name":"Charlene C. Knape","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Charlene Knape","raw_affiliation_strings":["Inivata Inc., Research Triangle Park, NC;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Inivata Inc., Research Triangle Park, NC;","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5061287088","display_name":"Ute Feger","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Ute Feger","raw_affiliation_strings":["Inivata Inc., Research Triangle Park, NC;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Inivata Inc., Research Triangle Park, NC;","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5051677819","display_name":"Giovanni Marsico","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Giovanni Marsico","raw_affiliation_strings":["Inivata Ltd, Cambridge, United Kingdom;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Inivata Ltd, Cambridge, United Kingdom;","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5075156511","display_name":"Karen Howarth","orcid":"https://orcid.org/0000-0002-1124-4583","observed_orcids":["https://orcid.org/0000-0002-1124-4583"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Karen Howarth","raw_affiliation_strings":["Inivata Ltd, Cambridge, United Kingdom;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Inivata Ltd, Cambridge, United Kingdom;","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5070245248","display_name":"Eric P. Winer","orcid":"https://orcid.org/0000-0002-8819-1723","observed_orcids":["https://orcid.org/0000-0002-8819-1723"]},"institutions":[{"id":"https://openalex.org/I32971472","display_name":"Yale University","ror":"https://ror.org/03v76x132","country_code":"US","type":"education","lineage":["https://openalex.org/I32971472"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Eric P. Winer","raw_affiliation_strings":["Yale University, New Haven, CT;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Yale University, New Haven, CT;","institution_ids":["https://openalex.org/I32971472"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5022319770","display_name":"NU Lin","orcid":"https://orcid.org/0000-0003-2263-5413","observed_orcids":["https://orcid.org/0000-0003-2263-5413"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Nancy U. Lin","raw_affiliation_strings":["Dana-Farber Cancer Institute, Boston, MA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dana-Farber Cancer Institute, Boston, MA;","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5088801158","display_name":"Heather Anne Parsons","orcid":"https://orcid.org/0000-0001-8178-6612","observed_orcids":["https://orcid.org/0000-0001-8178-6612"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Heather Anne Parsons","raw_affiliation_strings":["Dana-Farber Cancer Institute, Boston, MA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dana-Farber Cancer Institute, Boston, MA;","institution_ids":["https://openalex.org/I4210117453"]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":4,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":7,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"40","issue":"16_suppl","first_page":"103","last_page":"103"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11287","display_name":"Cancer Genomics and Diagnostics","score":0.98580002784729,"subfield":{"id":"https://openalex.org/subfields/1306","display_name":"Cancer Research"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T11287","display_name":"Cancer Genomics and Diagnostics","score":0.98580002784729,"subfield":{"id":"https://openalex.org/subfields/1306","display_name":"Cancer Research"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10183","display_name":"Breast Cancer Treatment Studies","score":0.00559999980032444,"subfield":{"id":"https://openalex.org/subfields/1306","display_name":"Cancer Research"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10769","display_name":"BRCA gene mutations in cancer","score":0.0052999998442828655,"subfield":{"id":"https://openalex.org/subfields/1311","display_name":"Genetics"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/circulating-tumor-dna","display_name":"circulating tumor DNA","score":0.9980000257492065},{"id":"https://openalex.org/keywords/late-recurrence","display_name":"late recurrence","score":0.7369999885559082},{"id":"https://openalex.org/keywords/hormone-receptor-positive-breast-cancer","display_name":"hormone receptor-positive breast cancer","score":0.9779999852180481},{"id":"https://openalex.org/keywords/her2-negative-breast-cancer","display_name":"HER2-negative breast cancer","score":0.9940000176429749},{"id":"https://openalex.org/keywords/measurable-residual-disease","display_name":"minimal residual disease","score":0.7829999923706055},{"id":"https://openalex.org/keywords/liquid-biopsy","display_name":"liquid biopsy","score":0.9259999990463257},{"id":"https://openalex.org/keywords/somatic-mutations","display_name":"somatic mutations","score":0.6669999957084656},{"id":"https://openalex.org/keywords/adjuvant-endocrine-therapy","display_name":"adjuvant endocrine therapy","score":0.7630000114440918},{"id":"https://openalex.org/keywords/adjuvant-chemotherapy","display_name":"adjuvant chemotherapy","score":0.6949999928474426},{"id":"https://openalex.org/keywords/distant-recurrence","display_name":"distant recurrence","score":0.6650000214576721},{"id":"https://openalex.org/keywords/long-term-follow-up","display_name":"long-term follow-up","score":0.5410000085830688},{"id":"https://openalex.org/keywords/ctdna-dynamics","display_name":"ctDNA dynamics","score":0.42500001192092896},{"id":"https://openalex.org/keywords/prognostic-factors","display_name":"prognostic factors","score":0.656000018119812},{"id":"https://openalex.org/keywords/disease-free-survival","display_name":"disease-free survival","score":0.3059999942779541}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9111347794532776},{"id":"https://openalex.org/C530470458","wikidata":"https://www.wikidata.org/wiki/Q128581","display_name":"Breast cancer","level":3,"score":0.6508526802062988},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.6476319432258606},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.5623670816421509},{"id":"https://openalex.org/C2781335228","wikidata":"https://www.wikidata.org/wiki/Q19596321","display_name":"Circulating tumor DNA","level":3,"score":0.5426924228668213},{"id":"https://openalex.org/C2779529041","wikidata":"https://www.wikidata.org/wiki/Q22349364","display_name":"Liquid biopsy","level":3,"score":0.5393517017364502},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.4933868944644928},{"id":"https://openalex.org/C2780283643","wikidata":"https://www.wikidata.org/wiki/Q2110267","display_name":"Primary tumor","level":4,"score":0.42857062816619873},{"id":"https://openalex.org/C23589133","wikidata":"https://www.wikidata.org/wiki/Q412005","display_name":"Hormone receptor","level":4,"score":0.4285479784011841},{"id":"https://openalex.org/C2775934546","wikidata":"https://www.wikidata.org/wiki/Q179991","display_name":"Biopsy","level":2,"score":0.4190061390399933},{"id":"https://openalex.org/C2779013556","wikidata":"https://www.wikidata.org/wiki/Q181876","display_name":"Metastasis","level":3,"score":0.19836094975471497}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1200/jco.2022.40.16_suppl.103","doi":"https://doi.org/10.1200/jco.2022.40.16_suppl.103","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2022.40.16_suppl.103","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","score":1.0,"id":"https://metadata.un.org/sdg/3"}],"sustainable_development_goals_aurora":[{"display_name":"Good health and well-being","score":0.8500000238418579,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4410812930","https://openalex.org/W4281993923","https://openalex.org/W4411489218","https://openalex.org/W4410805001","https://openalex.org/W7130715976","https://openalex.org/W7203744665","https://openalex.org/W4399667448","https://openalex.org/W4409626993","https://openalex.org/W4399122166","https://openalex.org/W4322775271"],"abstract_inverted_index":{"103":[0,204],"Background:":[1],"Hormone":[2],"receptor\u2013positive":[3],"breast":[4],"cancer":[5,41],"(HR+":[6],"BC)":[7],"is":[8,58,470],"the":[9,63],"most":[10,258],"common":[11],"cause":[12],"of":[13,18,29,81,117,134,190,240,278,295,381,435,452],"BC-related":[14],"death.":[15],"Over":[16],"half":[17],"metastatic":[19,194,332,363],"recurrences":[20],"occur":[21],"\u2265":[22,76,106,112,440],"5":[23,77,119,293,327,441],"years":[24,45],"(y)":[25],"from":[26,79,235,246,298,304,318,324,409,443],"diagnosis.":[27,444],"Detection":[28],"minimal":[30],"residual":[31],"disease":[32],"(MRD)":[33],"via":[34],"circulating":[35],"tumor":[36,150,210,379],"DNA":[37],"(ctDNA)":[38],"can":[39,485],"identify":[40,153],"recurrence":[42,118,333,364,393],"months":[43],"to":[44,54,152,169,230,300,372],"in":[46,62,74,429,449,458],"advance":[47],"and":[48,71,126,136,156,212,228,257,320,334,349,405,416],"may":[49],"be":[50],"an":[51],"important":[52],"tool":[53],"guide":[55],"therapy.":[56],"Little":[57],"known":[59],"about":[60],"ctDNA":[61,69,368,375,410,413,427,445,455],"late":[64,430],"adjuvant":[65,274,287,431],"setting.":[66],"We":[67],"investigated":[68],"dynamics":[70],"clinical":[72,200,392,487],"outcomes":[73],"pts":[75,177,185,205,214,251,265,284,328,336,343,352,361,388,436,460,474],"y":[78,120,294,306,317,323,442],"diagnosis":[80,122,299,319],"high-risk":[82,89],"early-stage":[83],"HR+":[84,90,432],"BC.":[85,433],"Methods:":[86],"Patients":[87],"with":[88,97,114,362,367,399],"BC":[91],"(T3-4":[92],"or":[93,95,101,110],"N2-3":[94],"T1":[96],"3+":[98],"lymph":[99],"nodes,":[100],"T2N1":[102],"[and":[103],"Oncotype":[104],"RS":[105],"26;":[107],"grade":[108],"3;":[109],"Ki-67":[111],"20%])":[113],"no":[115,400],"evidence":[116],"after":[121],"were":[123,130,186,221,344,353,365],"prospectively":[124],"identified":[125,447],"consented.":[127],"Plasma":[128],"samples":[129,234,242],"collected":[131],"at":[132,137,276,346,355,378,394,439,475],"time":[133,277,357],"consent":[135],"routine":[138],"visits":[139],"every":[140],"6-12":[141],"mos.":[142,374],"Whole-exome":[143],"sequencing":[144],"(WES)":[145],"was":[146,314,376,456],"performed":[147],"on":[148,273,426],"primary":[149],"tissue":[151],"somatic":[154],"mutations":[155],"design":[157],"for":[158,188,472],"each":[159],"patient":[160,244],"a":[161,164],"RaDaR":[162,219],"assay,":[163],"tumor-informed":[165],"liquid":[166],"biopsy":[167],"test":[168,231],"detect":[170],"plasma":[171,233,241],"ctDNA.":[172],"Per":[173],"current":[174],"practice":[175],"standards,":[176],"did":[178],"not":[179,390,463],"undergo":[180],"regular":[181],"surveillance":[182],"imaging.":[183],"All":[184,264],"followed":[187],"development":[189],"local":[191],"and/or":[192],"distant":[193,331,453],"recurrence,":[195],"as":[196],"determined":[197],"by":[198],"their":[199],"provider.":[201],"Results:":[202],"Of":[203,282],"enrolled,":[206],"85":[207],"had":[208,215,253,338,389,391,437],"sufficient":[209],"tissue,":[211],"83":[213,236],"successful":[216],"WES.":[217],"Personalized":[218],"assays":[220],"designed":[222],"targeting":[223],"12-51":[224],"variants":[225],"(median,":[226,248,307,383],"36),":[227],"used":[229],"219":[232],"pts.":[237],"The":[238],"number":[239],"per":[243],"ranged":[245,303],"1-7":[247],"2).":[249],"57":[250],"(68.7%)":[252],"stage":[254],"3":[255],"disease,":[256],"(75,":[259],"90.4%)":[260],"received":[261,266,291],"curative-intent":[262],"chemotherapy.":[263],"endocrine":[267],"therapy":[268],"(ET).":[269],"39":[270],"(47%)":[271],"remained":[272],"ET":[275],"last":[279],"follow":[280,312,396,401,468],"up.":[281],"44":[283],"who":[285,461],"completed":[286],"ET,":[288],"41":[289],"(93.2%)":[290],">":[292],"treatment.":[296],"Time":[297],"first":[301,325,424],"sample":[302],"4.9-20":[305],"8.4":[308],"y).":[309],"Median":[310],"(range)":[311],"up":[313,371,402,469],"10.2":[315],"(6.7-22.3)":[316],"1.8":[321],"(0-3.6)":[322],"sample.":[326],"(6%)":[329],"developed":[330],"2":[335,459],"(2.4%)":[337],"locoregional":[339],"recurrence.":[340,454,466],"4/83":[341],"(5%)":[342],"MRD+":[345,354,387],"study":[347],"entry":[348],"8/83":[350],"(10%)":[351],"any":[356],"point.":[358],"5/5":[359],"(100%)":[360],"MRD+,":[366],"lead":[369],"times":[370],"37.6":[373],"detected":[377,457],"fractions":[380],"0.0027-26.84%":[382],"0.396%).":[384],"2/8":[385],"(25%)":[386],"latest":[395],"up,":[397],"one":[398,406],"since":[403],"detection":[404,411,428],"15.4":[407],"mos":[408],"(with":[412],"levels":[414],"0.045%":[415],"26.84%).":[417],"Conclusions:":[418],"Here":[419],"we":[420],"report\u2014to":[421],"our":[422],"knowledge\u2014the":[423],"data":[425],"10%":[434],"MRD":[438,448],"analysis":[446],"all":[450],"cases":[451],"have":[462],"yet":[464],"experienced":[465],"Longer":[467],"necessary":[471],"these":[473],"high":[476],"risk.":[477],"Additional":[478],"studies":[479],"will":[480],"determine":[481],"if":[482],"ctDNA-guided":[483],"intervention":[484],"alter":[486],"outcomes.":[488]},"counts_by_year":[{"year":2025,"cited_by_count":2},{"year":2024,"cited_by_count":2},{"year":2023,"cited_by_count":1},{"year":2022,"cited_by_count":2}],"updated_date":"2026-10-16T09:59:22.235173","created_date":"2022-06-13T00:00:00"}